In patients with moderate‑to‑severe UC who have failed anti‑TNF therapy, how does risankizumab compare to vedolizumab in achieving clinical remission at 52 weeks

What is known

- Risankizumab targets the IL-23 p19 subunit. ¹ - Vedolizumab targets α4β7 integrin. ²

What is unknown / caveats

- No head-to-head comparison of risankizumab versus vedolizumab for 52-week clinical remission in anti-TNF–failed moderate-to-severe ulcerative colitis is present in the excerpts. - The available data describe each agent's mechanism but provide no comparative remission outcomes between them.

## References

1. Rommel FR, Bergheim C, Jerrentrup I, Weber S, Jenke A. Efficacy of Modified Upadacitinib Dosing in Pediatric Refractory IBD: A Case-Based Analysis. Children (Basel). 2025. PMID: 41007133.

2. Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med. 2019. PMID: 31817972.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._